98%
921
2 minutes
20
Objective: To develop core outcome sets (COS) for miscarriage management and prevention.
Design: Modified Delphi survey combined with a consensus development meeting.
Setting: International.
Population: Stakeholder groups included healthcare providers, international experts, researchers, charities and couples with lived experience of miscarriage from 15 countries: 129 stakeholders for miscarriage management and 437 for miscarriage prevention.
Methods: Modified Delphi method and modified nominal group technique.
Results: The final COS for miscarriage management comprises six outcomes: efficacy of treatment, heavy vaginal bleeding, pelvic infection, maternal death, treatment or procedure-related complications, and patient satisfaction. The final COS for miscarriage prevention comprises 12 outcomes: pregnancy loss <24 weeks' gestation, live birth, gestation at birth, pre-term birth, congenital abnormalities, fetal growth restriction, maternal (antenatal) complications, compliance with intervention, patient satisfaction, maternal hospitalisation, neonatal or infant hospitalisation, and neonatal or infant death. Other outcomes identified as important were mental health-related outcomes, future fertility and health economic outcomes.
Conclusions: This study has developed two core outcome sets, through robust methodology, that should be implemented across future randomised trials and systematic reviews in miscarriage management and prevention. This work will help to standardise outcome selection, collection and reporting, and improve the quality and safety of future studies in miscarriage.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/1471-0528.17484 | DOI Listing |
Sex Reprod Health Matters
September 2025
Senior Research Scientist, Guttmacher Institute, New York, United States.
Since the release of the Supreme Court decision in June 2022, researchers have been working to better understand the impact that the growing number of abortion restrictions are having on the provision of and access to abortion services in the United States (US). Less is known about the impact of abortion restrictions on the provision of sexual and reproductive health (SRH) services more broadly, including at clinics that do not directly offer abortion. Between November 2023 and February 2024, we conducted interviews with SRH managers, clinic managers, and other administrators at publicly funded SRH clinics around the US to generate evidence on the effects of state-level abortion restrictions on the provision of abortion and related services, such as pregnancy options counselling and abortion referrals, at facilities providing contraceptive services.
View Article and Find Full Text PDFInt J Surg Case Rep
September 2025
Department of Obstetrics and Gynaecology, Aga Khan Hospital, Dar es Salaam, Tanzania.
Introduction: Uterine fibroids are a common cause of infertility, and myomectomy remains a key surgical intervention to improve reproductive outcomes. However, the occurrence of an undetected pregnancy during myomectomy is rare and poses significant clinical risks.
Case Presentation: We report a 34-year-old woman, nulliparous with a history of secondary infertility and three first-trimester miscarriages.
Cureus
August 2025
Obstetrics and Gynaecology, Whittington Health National Health Service (NHS) Trust, London, GBR.
Hematometra is an uncommon and delayed complication following the surgical management of miscarriage. When it occurs in the early postoperative period, it is sometimes referred to as "Redo syndrome". We present the case of a 39-year-old woman who developed this rare condition following a suction and evacuation procedure performed for a missed miscarriage.
View Article and Find Full Text PDFEndocrinol Diabetes Metab Case Rep
July 2025
Summary: Primary hyperparathyroidism (PHPT) is a rare condition during pregnancy, but it is associated with significant maternal and fetal risks, including miscarriage, preeclampsia, and preterm birth. Hyperparathyroidism-jaw tumor (HPT-JT) syndrome is a rare genetic form of PHPT caused by mutations in the CDC73 gene. Managing PHPT during pregnancy is particularly challenging.
View Article and Find Full Text PDFEClinicalMedicine
September 2025
Shanghai Key Laboratory of Maternal Fetal Medicine, Shanghai Institute of Maternal-Fetal Medicine and Gynecologic Oncology, Shanghai First Maternity and Infant Hospital, School of Medicine, Tongji University, Shanghai, 201204, China.
Background: Recurrent spontaneous abortion (RSA) poses a significant clinical challenge for childbearing women. Cyclosporine A (CsA), first introduced by our group for RSA treatment, has gained wide clinical application in China, yet remains underutilized internationally. With this systematic review, we aimed to systematically evaluate the efficacy and safety of CsA based therapy in the management of RSA.
View Article and Find Full Text PDF